+

PE20040701A1 - Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos - Google Patents

Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos

Info

Publication number
PE20040701A1
PE20040701A1 PE2003000724A PE2003000724A PE20040701A1 PE 20040701 A1 PE20040701 A1 PE 20040701A1 PE 2003000724 A PE2003000724 A PE 2003000724A PE 2003000724 A PE2003000724 A PE 2003000724A PE 20040701 A1 PE20040701 A1 PE 20040701A1
Authority
PE
Peru
Prior art keywords
phenyl
indolinone
medicines
preparation
substituted
Prior art date
Application number
PE2003000724A
Other languages
English (en)
Inventor
Armin Heckel
Gerald Jurgen Roth
Frank Hilberg
Thorsten Lehmann-Lintz
Jorg Kley
Meel Jacobus C A Van
Ulrike Tontsch-Grunt
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/de
Priority claimed from DE10328533A external-priority patent/DE10328533A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040701A1 publication Critical patent/PE20040701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X ES O; R1 ES H; R2 ES F, Cl, Br, CN; R3 ES FENILO SUSTITUIDO O NO CON F, Cl, I, ALCOXI, ENTRE OTROS; R4 ES FENILO SUSTITUIDO O NO CON ALQUILO C1-C3, GUANIDINO, MONO- O DI-(ALQUIL C1-C2), ENTRE OTROS; R5 Y R6 SON H. SON COMPUESTOS PREFERIDOS: 3-Z-[1-(4-(DIMETILAMINOMETIL-ANILINO)-1-(3-(2-CARBOXI-ETIL)-FENIL)-METILEN]-6-CLORO-2-INDOLINONA; 3-Z-[1-(4-(N-4-METIL-PIPERAZIN-1-IL-METILCARBONIL)-N-METIL-AMINO)-ANILINO)-1-(4-(2-CARBOXI-ETIL)-FENIL)-METILEN]-6-FLUOR-2-INDOLINONA. SE REFIERE TAMBIEN A UNA COMOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE RECEPTORES TIROSINAS QUINASAS, ASI COMO SOBRE LA PROLIFERACION DE CELULAS ENDOTELIALES Y DIVERSAS CELULAS TUMORALES
PE2003000724A 2002-07-23 2003-07-21 Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos PE20040701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (de) 2002-07-23 2002-07-23 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10328533A DE10328533A1 (de) 2003-06-24 2003-06-24 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20040701A1 true PE20040701A1 (es) 2004-11-30

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000724A PE20040701A1 (es) 2002-07-23 2003-07-21 Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos

Country Status (25)

Country Link
EP (1) EP1523473B1 (es)
JP (1) JP4401291B2 (es)
KR (2) KR20050052456A (es)
CN (1) CN1318403C (es)
AR (1) AR041188A1 (es)
AU (2) AU2003254557B2 (es)
BR (1) BR0312799A (es)
CA (1) CA2493436C (es)
DK (1) DK1523473T3 (es)
EA (1) EA008623B1 (es)
EC (1) ECSP055567A (es)
ES (1) ES2409062T3 (es)
HK (1) HK1081554A1 (es)
HR (1) HRP20050069A2 (es)
IL (1) IL166404A0 (es)
MX (1) MXPA04012937A (es)
MY (1) MY138141A (es)
NO (1) NO20050937L (es)
PE (1) PE20040701A1 (es)
PL (2) PL397821A1 (es)
RS (1) RS20050047A (es)
SA (1) SA03240430B1 (es)
TW (1) TWI343375B (es)
UY (1) UY27903A1 (es)
WO (1) WO2004009547A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
NZ563448A (en) * 2005-04-28 2011-01-28 Boehringer Ingelheim Int Benzofuranone derivatives for treating inflammatory diseases
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
EP2238108B1 (en) * 2008-01-25 2012-08-29 Boehringer Ingelheim International GmbH Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
CN101970407A (zh) * 2008-01-25 2011-02-09 贝林格尔.英格海姆国际有限公司 6-氟-1,2-二氢-2-氧代-3h-吲哚-3-亚基衍生物的制备方法
JP5651110B2 (ja) 2008-07-29 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
JP6263124B2 (ja) * 2012-10-17 2018-01-17 国立大学法人 岡山大学 化合物、その互変異性体、幾何異性体、乃至それらの塩、及びそれらの製造方法、抗菌剤、並びに感染症治療薬
EP2930167B1 (en) * 2012-12-06 2018-11-21 KBP Biosciences Co., Ltd. An indolinone derivative as tyrosine kinase inhibitor
CN105461609B (zh) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104973A3 (en) * 1998-09-25 2002-06-28 Boehringer Ingelheim Pharma Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes, process for their use and medicaments containing them
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US7005444B2 (en) * 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
AU2002341881B2 (en) * 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
TWI343375B (en) 2011-06-11
CA2493436C (en) 2011-11-08
SA03240430B1 (ar) 2008-03-23
PL397821A1 (pl) 2012-03-12
ECSP055567A (es) 2005-04-18
KR20120003025A (ko) 2012-01-09
TW200413314A (en) 2004-08-01
UY27903A1 (es) 2004-02-27
DK1523473T3 (da) 2013-06-03
KR20050052456A (ko) 2005-06-02
WO2004009547A1 (de) 2004-01-29
RS20050047A (en) 2007-09-21
EA200500148A1 (ru) 2005-08-25
CN1318403C (zh) 2007-05-30
MXPA04012937A (es) 2005-05-16
MY138141A (en) 2009-04-30
NO20050937L (no) 2005-02-21
EP1523473B1 (de) 2013-02-27
JP4401291B2 (ja) 2010-01-20
ES2409062T3 (es) 2013-06-24
EA008623B1 (ru) 2007-06-29
BR0312799A (pt) 2005-05-03
CA2493436A1 (en) 2004-01-29
HRP20050069A2 (en) 2005-12-31
CN1668589A (zh) 2005-09-14
AU2003254557A1 (en) 2004-02-09
HK1081554A1 (en) 2006-05-19
AU2003254557B2 (en) 2010-07-22
JP2005533841A (ja) 2005-11-10
AR041188A1 (es) 2005-05-04
AU2010202845A1 (en) 2010-07-22
IL166404A0 (en) 2006-01-15
EP1523473A1 (de) 2005-04-20
PL374879A1 (en) 2005-11-14

Similar Documents

Publication Publication Date Title
PE20040701A1 (es) Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
RU2004132204A (ru) Имидазоконденсированные соединения
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
CY1112916T1 (el) 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
ATE433981T1 (de) Heterocyclische verbindungen
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE266021T1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
TW200732303A (en) Novel fused pyrrole derivatives
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
PE20090042A1 (es) Analogos de ciclopamina
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
TR200402069T4 (tr) Difenilüre türevleri ve bunların alfa 2/5-HT2c antagonisti olarak kullanılması
RS52700B (en) SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND
CO5050296A1 (es) Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
SE0104250D0 (sv) Heterocyclic compounds
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0203303D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载